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Methicillin-resistant Staphylococcus aureus (MRSA)
is a major nosocomial and community-acquired
pathogen for which few existing antibiotics are effi-
cacious. Here we describe two structurally related
synthetic compounds that potentiate b-lactam
activity against MRSA. Genetic studies indicate that
these agents target SAV1754 based on the following
observations: (i) it has a unique chemical hypersensi-
tivity profile, (ii) overexpression or point mutations
are sufficient to confer resistance, and (iii) genetic
inactivation phenocopies the potentiating effect of
these agents in combination with b-lactams. Further,
we demonstrate these agents inhibit peptidoglycan
synthesis. Because SAV1754 is essential for growth
and structurally related to the recently reported
peptidoglycan flippase of Escherichia coli, we spec-
ulate it performs an analogous function in S. aureus.
These results suggest that SAV1754 inhibitors might
possess therapeutic potential alone, or in combina-
tion with b-lactams to restore MRSA efficacy.
INTRODUCTION
Staphylococcus aureus is amajor human pathogen causing both
hospital and community-acquired infections. Successive acqui-
sition of resistance to most classes of antibiotics has seriously
limited treatment options. In particular, methicillin-resistant
S. aureus (MRSA), which is highly cross-resistant to essentially
all other b-lactam antibiotics in this class, constitutes over
50% of all clinical isolates identified in U.S. hospitals during
a surveillance period spanning 1998–2005 (Styers et al., 2006).
Moreover, the number of serious infections caused by MRSA
alone in the United States throughout 2005 approached nearly
95,000 cases, of which almost 19,000 related fatalities were esti-
mated, thus exceeding the U.S. death toll attributed to HIV/AIDS
in the same year (Klevens et al., 2007; Bancroft, 2007).
b-Lactams acetylate an essential transpeptidation activity
common to a family of penicillin-binding proteins (PBPs), therebyChemistry & Biology 16, 8inhibiting peptidoglycan crosslinking and integrity of the cell wall
(van Heijenoort, 2001). The key resistance determinant to these
agents is an acquired gene, mecA, which encodes a penicillin-
binding protein (PBP2A) with markedly reduced affinity to b-lac-
tams compared with native S. aureus PBPs (Matsuhashi et al.,
1986; Song et al., 1987; de Lencastre et al., 2007). MRSA resis-
tance to b-lactams is achieved by the cooperative function of
PBP2A and PBP2, which provide transpeptidation and transgly-
cosylation activities, respectively, necessary to assemble pepti-
doglycan precurors and adequately crosslink these polymers
within the cell wall (Pinho et al., 2001a; Scheffers and Pinho,
2005).
PBP2A and PBP2 represent important antibiotic targets that
might be exploited to develop new efficacious agents against
MRSA (Pinho et al., 2001b; Bush et al., 2007; Projan and Brad-
ford, 2007). However, a number of auxiliary genes have also
been identified by transposon-based screens, which, if inacti-
vated, also dramatically increase MRSA susceptibility to b-lac-
tams (Berger-Ba¨chi et al., 1992; de Lencastre and Tomasz,
1994). Interestingly, many of these genes that are required for
the maximal expression of resistance by PBP2A are also
involved in peptidoglycan precursor biosynthesis and turnover
(Berger-Ba¨chi and Rohrer, 2002; de Lencastre et al., 1999;
Sobral et al., 2003; Gardete et al., 2004). These and other studies
(Pinho and Errington, 2003; Miller et al., 2004; Memmi et al.,
2008; Sieradzki et al., 2008) emphasize the diversity of achiev-
able points of genetic potentiation with b-lactams that could
be mimicked by cognate inhibitors. Therefore, an alternative
approach to developingMRSA active agents would involve iden-
tifying inhibitors that target these factors, which in combination
with a b-lactam, would restore the activity of the latter.
Conceptually, target-specific inhibitors of b-lactam potenti-
ating determinants should phenocopy their genetic inactivation.
Moreover, provided such inhibitors are target specific, they
serve as chemical probes to identify essential factors that might
be refractory to transposon insertional inactivation screens. To
identify compounds that synergize in combination with a b-lac-
tam, a high-throughput screen (HTS) against our chemical library
was performed using the MRSA clinical isolate, COL, grown
in the presence of a sub-minimal inhibitory concentration (MIC)
of ertapenem. Here we describe a structurally related class
of inhibitors that synergize with the queried b-lactam and37–848, August 28, 2009 ª2009 Elsevier Ltd All rights reserved 837
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anism-of-action (MOA) profiling (Donald et al., 2009 [this issue of
Chemistry & Biology]) and confirmed by resistance mapping,
these agents target the uncharacterized gene SAV1754. In this
study, we demonstrate that SAV1754 is an essential gene and
show that its inactivation by chemical or genetic means results
in cell wall defects, including quantitative defects in peptido-
glycan synthesis and aberrant cell wall peptidoglycan staining.
In addition, genetic inactivation of SAV1754 by antisense inter-
ference dramatically restores COL susceptibility to b-lactams,
similar to that achieved by antisense interference of pbp2. Based
on SAV1754 phenotypes and its structural similarity to the
recently described E. coli protein, MurJ (Ruiz, 2008; Inoue
et al., 2008), we propose SAV1754 might function similarly as a
peptidoglycan flippase required to translocate lipid-linked pepti-
doglycan precursors to nascent sites of cell wall synthesis.
RESULTS
Characterization of an Indole Series of Small Molecules
that Potentiate the Effects of Carbapenem Antibiotics
To identify chemical entities that restore the activity of the carba-
penem class of b-lactams against MRSA, we performed an HTS
of our synthetic chemical library (8mMfinal concentration) against
the MRSA clinical isolate, COL, grown in the presence of a
Figure 1. DMPI and CDFI Chemical Struc-
tures and Analysis of Synergy in Combina-
tion with Imipenem
Synergy of DMPI (A) and CDFI (B) in combination
with imipenem were tested against MRSA and
MRSE clinical isolates, COL and CLB26329,
respectively. Drug concentrations and fraction
inhibitory concentrations (FIC) used to evaluate
synergism are indicated. Note synergism is
achieved by the combination of the two agents
fully inhibiting growth provided their individual
drug concentrations sum to a FICI value % 0.5
(indicated by the diagonal line).
sub-MIC (2 mg/ml) of ertapenem. Here
we characterize two structurally-related
compounds identified that potentiate
the effects of carbapenems; 3-{1-[(2,3-
Dimethylphenyl)methyl]piperidin-4-yl}-1-
methyl-2-pyridin-4-yl-1H-indole (DMPI)
and 2-(2-Chlorophenyl)-3-[1-(2,3-dime-
thylbenzyl)piperidin-4-yl]-5-fluoro-1H-in-
dole (CDFI) (Figure 1). To confirm DMPI
and CDFI potentiate the activity of carba-
penems, their synergistic effects in com-
bination with imipenem were tested.
DMPI and CDFI both displayed strong
synergy in combination with imipenem
againstCOL;whereas 32mg/ml imipenem
was required as a single agent to achieve
aminimum inhibitory concentration (MIC),
as little as 2 mg/ml imipenem in combina-
tion with 1 mg/ml of either DMPI or CDFI
was sufficient to inhibit COL (Figure 1; see Table S1 available on-
line). Indeed such synergistic effectswere observed overmultiple
imipenem concentrations tested. CDFI also displayed synergy in
combination with imipenem against the methicillin resistant
Staphylococcus epidermidis (MRSE) clinical isolate CLB26329
across multiple imipenem concentrations, despite MRSE dis-
playing reduced susceptibility to either agent alone. Further,
CDFI displayed marked potentiation of imipenem against methi-
cillin-resistant coagulase negative Staphylococci (MRCNS) as
well as the community-acquired MRSA strain, USA300 (data
not shown). Interestingly, no synergismbetweenany of the above
agents was observed against methicillin-sensitive S. aureus
(MSSA) (Table S1), suggesting that their synergism is specific in
the context of the mechanism of b-lactam resistance among
these bacteria.
Antibacterial activity of DMPI and CDFI was assessed against
a panel of Gram-positive and Gram-negative bacteria using
standard CLSI protocols (Table S2). DMPI displays comparable
activity against MSSA and MRSA (MIC = 16 mg/ml) but weak
growth inhibitory activity versus other pathogenic bacteria
tested. CDFI displays significantly improved activity against
MSSA and MRSA (MIC = 2 mg/ml) as well as improved spectrum
including Bacillus subtilis (MIC = 4 mg/ml), Streptococcus pneu-
moniae (MIC = 4 mg/ml), and Enterococcus faecium (MIC80 =
4 mg/ml). Although both compounds lack activity against all838 Chemistry & Biology 16, 837–848, August 28, 2009 ª2009 Elsevier Ltd All rights reserved
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and Escherichia coli), this might reflect their inability to penetrate
the outer membrane and/or efficient efflux from the cell. Consis-
tent with this possibility, measurable growth inhibitory activity
of DMPI and CDFI (MICs were 32 mg/ml and 4 mg/ml, respec-
tively) were obtained against a permeablized E. coli strain,
MB5746 (Onishi et al., 1996), which is defective for TolC-medi-
ated efflux and has the lpxC101 mutation which impairs lipopoly-
saccharide biosynthesis and increases permeability of the outer
membrane.
Macromolecular Labeling Studies Demonstrate
that Imipenem Potentiators Affect Cell Wall Synthesis
The effects of DMPI and CDFI on macromolecular synthesis
pathways were determined in MSSA S. aureus strain EP167 by
measuring the relative incorporation of radiolabeled precursors
of DNA, RNA, protein, phospholipid, and cell wall synthesis
Figure 2. Inhibitory Effects of DMPI and
CDFI on Macromolecular Synthesis
(A and B) DMPI (A) and CDFI (B) inhibitory effects
across the indicated drug concentrations were
determined bymeasuring incorporation of radiola-
beled precursors of either DNA (14C-thymidine),
RNA (3H-uridine), phospholipid (2-3H-glycerol),
protein (3H-leucine), or cell wall (14C-glycine)
synthesis in S. aureus strain EP167. Arrows indi-
cate MIC for each compound.
(C) Control compounds for inhibiting synthesis of
DNA (Ciprofloxacin; Cip), RNA (Rifampicin; Rif),
phospholipid (thiolactomycin; Tlm), protein (eryth-
romycin; Ery), and cell wall (penicillin G; Png) are
shown at the single sub MIC concentration (mg/
ml) indicated in brackets. Note that protein
synthesis is inhibited by both erythromycin and
rifampicin control drug treatments, as expected.
across a range of concentrations. Treat-
ment with either compound at multiple
sub-MIC levels resulted in marked inhibi-
tion of peptidoglycan synthesis (Figure 2).
Inhibition was selective for cell wall
synthesis; all other macromolecular path-
ways assayed were either unaffected or
only modestly inhibited (e.g., CDFI’s
effect on protein synthesis) at concentra-
tions approaching their MIC’s. Thus the
primary growth inhibitory effect of DMPI
and CDFI relate to perturbing cell wall
biosynthesis.
Antisense Interference Profiling
Predicts Imipenem Potentiators
Target SAV1754
To corroborate that DMPI and CDFI act
on cell wall biosynthesis, and to poten-
tially identify the step in the peptido-
glycan biosynthetic pathway at which
these compounds might act, we applied
an antisense-induced strain sensitivity
(AISS) profiling assay described in the accompanying paper by
Donald et al. published in this issue of Chemistry & Biology (Don-
ald et al., 2009). Briefly, AISS profiling relies on gene-specific
antisense interference transcripts under the control of a
xylose-inducible promoter to reduce expression of the cognate
target, thereby sensitizing the strain to compounds that act
through the partially depleted gene product (Forsyth et al.,
2002). By performing this analysis in parallel with a compendium
of 245 essential genes across a range of partially inhibitory
compound doses, target-specific chemical hypersensitivity
phenotypes might be identified that predict the MOA of a
compound of interest, including the drug target and/or affected
cellular pathway. Indeed, in the accompanying report by Phillips
and colleagues, AISS profiling has been successfully applied to
reflect the known MOA among a spectrum of known antibiotics
affecting DNA, RNA, fatty acid, protein synthesis, and cell wall
biosynthesis (Donald et al., 2009).Chemistry & Biology 16, 837–848, August 28, 2009 ª2009 Elsevier Ltd All rights reserved 839
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EC50 values (ug/ml)
Figure 3. DMPI and CDFI Mechanism of
Action Studies and SAV1754 Target Valida-
tion
(A) Two-dimensional cluster of 19 experiments and
seven antisense strains displaying significant
hypersensitivity for DMPI, CDFI, and/or compound
D. Strain depletions are depicted in magenta,
strain resistances in cyan. The thresholds for
including strains in the cluster analysis are > 5-
fold depletion, p value % 0.01 in three or more
experiments. The compound name is followed by
the treatment concentration. All three compounds
share similar strain depletion profiles at all
compound concentrations, with the most signifi-
cantly depleted strain identified expressing an
antisense interference fragment complementary
to 131 nucleotides of the 30 end of the SAV1754
transcript as well as 30 nucleotides of the adjacent
50 end of SAV1753 (shown in red).
(B) Episomal expression of SAV1754 confers resis-
tance to inhibitors. Dose response for inhibition of
RN4220 by DMPI, CDFI, and compound D.
Compared with the control strain (plasmid pTETl5,
dotted lines), EC50 values with the SAV1754
expression vector strain (plasmid pTET15
SAV1754, solid lines) are increased approximately
10-fold for DMPI and 4-fold for CDFI and 20-fold
for compound D. Cells were grown for 10 hr in
LB media supplemented with chloramphenicol
(34 mg/ml) and anhydrotetracycline inducer
(20 ng/ml). Dose-response curves were fitted
using a four parameter logistic equation (Graph-
Pad Prism Software) with error bars representing
the standard error of the mean (SEM) of duplicate
samples.
(C) SAV1754 is essential for S. aureus growth.
RN4220 and COL strains maintaining the
SAV1754 antisense plasmid were seeded in LB
agar and xylose induction of the SAV1754 anti-
sense achieved by spotting xylose as indicated.
Note prominent and xylose-dependent zones of
growth inhibition specific to SAV1754 antisense
induction. No growth inhibition was observed in
parallel spottings with RN4220 or COL strains
harboring the empty antisense vector pEPSA5
(not shown).AISS profiles in response to DMPI and CDFI were unique and
highly selective, with a single hypersensitive strain (SAV1754-
AS) identified as prominently and reproducibly depleted from
the population (Figure 3A). Based on S. aureus Mu50 genome
sequence annotation, antisense RNA expressed by SAV1754-
AS is complementary to 131 nucleotides of the 30 end of the
SAV1754 gene transcript as well as 30 nucleotides of the 50
end of the adjacent SAV1753 gene transcript. The open reading
frame (ORF) of these genes overlap with the terminal nucleotide
of SAV1754 (an adenosine) comprising the first nucleotide of the
start codon of the distal SAV1753 gene.
To explore the significance of the SAV1754-AS strain sensi-
tivity to DMPI and CDFI, we tested whether episomal SAV1754
overexpression confers resistance to these agents. Growth inhi-
bition was compared between RN4220 maintaining full-length840 Chemistry & Biology 16, 837–848, August 28, 2009 ª2009 ElsevSAV1754 placed under the control of a tetracycline-inducible
promoter (pTET15-SAV1754) versus the vector alone (pTET15).
Overexpression of SAV1754 under inducing conditions shifted
the EC50 value of both DMPI and CDFI approximately 10-fold
and 4-fold higher than observed for the vector control strain
(Figure 3B). Further, genetic depletion of SAV1754 by xylose-
induced antisense interference abolished growth in a xylose-
dependent manner, confirming that SAV1754 is essential in S.
aureus RN4220 (Figure 3C) as previously predicted (Mott et al.,
2008). SAV1754 gene essentiality was similarly demonstrated
in MRSA where, following transformation of the SAV1754-AS
plasmid into COL, xylose-dependent growth inhibition was
also observed (Figure 3C). These results suggest that the growth
inhibitory effects of DMPI and CDFI might be targeting the
product of the essential gene, SAV1754.ier Ltd All rights reserved
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containing 14 transmembrane helices. However, its functional role
is unknown.GenomicBLASTsearchesagainstNCBImicrobepro-
teome databases (www.ncbi.nlm.nih.gov/sutils/genom_table.cgi)
reveal that SAV1754 orthologs are restricted to Gram-positive
bacteria, including S. epidermidis (0.0), Bacillus cereus (7e-
89), B. anthracis (4e-87), B. subtilis (1e-85), E. faecalis (1e-49),
S. pneumoniae (3e-40), and Clostridium difficile (2e-35)
(Figure S1A). No close homolog to SAV1754 is present in human
genome databases. Interestingly, a recent report describes
SAV1754 (also known as SA1575 based on S. aureus strain
N315 genome annotation) as the target of a novel class of anti-
bacterial anthranilic acids that also inhibit cell wall biosynthesis
and their resistance maps to the SAV1754 locus (Mott et al.,
2008). Evaluating the most potent member of this class
(compound D) by AISS profiling corroborated its selective inhi-
bition of SAV1754, because the SAV1754-AS strain was
uniquely identified and markedly hypersensitive to compound
D across all drug concentrations tested (Figure 3A, and Donald
et al., 2009). As expected, overexpression of SAV1754 also
conferred resistance to compound D (Figure 3B), as previously
reported by Mott and colleagues. Further, macromolecular
labeling experiments confirm its primary effect on cell wall
synthesis (Figure S2; Mott et al., 2008), and like DMPI and
CDFI, compound D prominently synergized the activity of
Figure 4. Cell Wall Staining of Nascent
Peptidoglycan and Cell Division Septa
following Drug Treatment
Fluorescence images of Van-FL labeled S. aureus
RN4220 cells grown with a transient incubation of
excess D-serine (Pinho and Errington, 2003) and
subsequently grown 30 min in TSB medium at
30C in the presence of 2% DMSO as a mock
treatment (A) or treated at 2X MIC with DMPI (B),
compound D (C), or the control compound, novo-
biocin (D). As highlighted in (A), arrows indicate
different stages of septum formation; cells with
two fluorescent spots (yellow arrows) correspond
to early septum ring formation, and a solid fluores-
cent bar across the mid plane of the cell (white
arrows) corresponds to a complete septum. Note
that Van-FL staining of nascent peptidoglycan
localized to septa is markedly reduced by DMPI
and compound D, whereas strong Van-FL labeling
of peptidoglycan and septa are detected among
novobiocin-treated cells.
imipenem against COL (Figure S3).
Thus, DMPI, CDFI, and compound D
likely share a common drug target whose
cognate inhibitors effect cell wall biosyn-
thesis and synergize with carbapenems.
SAV1754 Inhibitors Disrupt
Peptidoglycan Deposition
into the Cell Wall
To test for additional cell wall inhibitory
effects caused by DMPI, CDFI, or com-
pound D, we utilized a previously
described fluorescein-conjugated van-
comycin (Van-FL) staining procedure (Pinho and Errington,
2003) to examine peptidoglycan deposition following compound
treatment of the MSSA strain RN4220. As expected, fluorescent
staining of control treated cells (n = 88 cells evaluated) identified
nascent peptidoglycan largely localized to the cell division site
and concentrated along the division septum (n = 48 or 55% of
cells scored), with only minor staining throughout the rest of
the cell wall (Figure 4). However, cells treated with DMPI at
2XMIC for 50 min resulted in a striking reduction in overall fluo-
rescence of new cell wall material and only 7%of cells displaying
clear septum straining. CDFI-treated cells were similarly affected
(data not shown). Further, compound-D-treated cells resulted in
a significant reduction in overall Van-FL staining of new wall
material, with weak staining of septa observed among only 4%
of cells (n = 137) scored. Novobiocin treatment under identical
conditions served as a negative control; strong Van-FL staining
of nascent peptidoglycan was localized to the septum among
30% of 124 cells analyzed. Therefore, Van-FL staining of cells
treated with these putative SAV1754 inhibitors supports their
proposed primary effect on cell wall biosynthesis.
Characterization of DMPI-Resistant Mutants
To corroborate theMOA of these compounds as SAV1754 inhib-
itors and imipenem potentiators, DMPI was chosen to select for
resistancemutants inS. aureus strain COL using 2 mg/ml DMPI inChemistry & Biology 16, 837–848, August 28, 2009 ª2009 Elsevier Ltd All rights reserved 841
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Compound ID Additive (mg/ml) Value COL COL-1 COL-2 COL-3
Imipenem None MICa 16 16 16 16
DPMI None MIC 4 128 128 128
DPMI Imipenem (4) MIC 0.13 32 32 64
DPMI Imipenem (4) FICIb 0.28 0.5 0.5 0.75
CDFI None MIC 2 128 128 128
CDFI Imipenem (4) MIC 0.25 64 64 64
CDFI Imipenem (4) FICI 0.38 0.75 0.75 0.75
Compound D None MIC 0.13 0.13 0.06 0.13
Compound D Imipenem (4) MIC 0.008 0.031 0.016 0.031
Compound D Imipenem (4) FICI 0.31 0.50 0.50 0.50
aMIC values are defined as the concentration of test compound that inhibits bacterial growth and were determined using standard CLSI protocols.
b FICI (fraction inhibitory concentration index) as a measure of synergy; FICI values% 0.5 defining synergy between the two agents.combination with 4 mg/ml imipenem. After 24 hr growth, sponta-
neous resistance occurred at a frequency of 1 3 109, sug-
gesting a single mutation is likely responsible for the resistance
phenotype. Three independent resistant mutants, COL-1,
COL-2, and COL-3, were evaluated for their susceptibility to
DMPI alone or in combination with a sub-inhibitory concentra-
tion of imipenem at 4 mg/ml. Each of the isolated mutants was
resistant to DMPI as a single agent, with MICs > 64 mg/ml and
> 16-fold relative the parental COL strain (Table 1). Further,
COL-1, COL-2, and COL-3 required 250–500-fold higher DMPI
levels than the parental COL strain to achieve the desired MIC
in combination with imipenem at 4 mg/ml. Because the resistant
isolates lack an altered susceptibility to imipenem as a single
agent, we conclude that the mutants are resistant to DMPI,
not imipenem. In addition, the synergistic effects of DMPI and
imipenem were not observed with the COL1-2, COL-2, and
COL-3 mutants (Figure S4 and Table S3). Similarly, each of
the three DMPI-resistant isolates displayed cross-resistance to
the structural analog, CDFI, and suppressed the synergistic
activity between CDFI and imipenem. No cross-resistance to
compound D was detected; only 2–4-fold differences in
compound DMIC values were observed among the DMPI-resis-
tant strains (Table 1; Figure S3).
To assesswhether theseDMPI resistantmutantsmap tomuta-
tions within SAV1754 or the adjacent ORF, SAV1753, (which
might also be potentially affected by the SAV1754 antisense tran-
script) as predicted by AISS profiling, both genes were fully
sequenced from COL-1, COL-2, and COL-3 isolates. In fact, all
three strains contain a distinct single missense mutation in the
SAV1754 ORF compared to the COL parental strain (Figure S5)
and no mutations were identified within SAV1753. COL-1
contains a G to T transition at nucleotide 131 of the SAV1754
ORF, causing a proline to glutamine amino acid substitution at
position 44 of the protein. COL-2 possesses a C to T transition
at nucleotide 766 of the SAV1754 ORF, resulting in a proline to
serine substitution at amino acid 257 of the protein. A base
change transition from A to G at nucleotide 54 of the SAV1754
ORF was also identified in COL-3, resulting in an isoleucine to
methionine substitution at amino acid position 18 of the protein.
Because each of these mutants conferred marked resistance to
DMPIandCDFIwithoutcross resistance tomultiple cellwall inhib-
itors (e.g., vancomycin, moenomycin, D-cycloserine, fosfomycin,842 Chemistry & Biology 16, 837–848, August 28, 2009 ª2009 Elsetunicamycin, or compoundD) or other agents (ciprofloxacin, line-
zolid, platensimycin, or clindamycin), it is unlikely SAV1754 plays
a general role in drug import or efflux (Table S4). Further, allelic
introduction of each of the three SAV1574 mutations into
RN4220 was sufficient to confer DMPI resistance (Figure 5).
As expected, each of these mutations was sufficient to provide
cross-resistance to CDFI but not compound D (Figure 5).
Collectively, these results strongly implicate SAV1754 as the
direct target of DMPI and CDFI and predict that its inactivation
potentiates the activity of imipenem.
Genetic Inactivation of SAV1754 Potentiates Imipenem
Activity against MRSA
Provided DMPI and CDFI potentiate imipenem activity against
COL by inhibiting SAV1754, a prediction can be made that
genetic inactivation of SAV1754 should similarly restore imipe-
nem activity in this genetic background. To test this possibility,
we examined antibiotic susceptibility of COL maintaining the
SAV1754-AS plasmid versus a control strain with empty vector.
Strains were seeded in agar media with or without the antisense
inducer (50 mM xylose). Genetic depletion of SAV1754 resulted
in a xylose-dependent hypersensitivity to imipenem as judged by
markedly increased zones of growth inhibition over a broad
range of imipenem levels tested (Figure 6; data not shown).
Further, depletion of SAV1754 resulted in pronounced hypersen-
sitivity across a wide range of additional b-lactams tested, in-
cluding ertapenem, cephalosporins (cefepime, ceftazidime, and
ceftriaxone), and piperacillin in combination with tazobactam
(Figure 6). Remarkably, SAV1754-based genetic potentiation of
b-lactams exceeded that achieved by PBP2-AS inactivation,
which is a known target of these agents and thus serves as a
positive control (Figure 6). The PBP2-AS antibiotic sensitivity
profile was restricted to a subset of cell wall inhibitors including
imipenem, ertapenem, and vancomycin. Notably, mutations in
multiple cell wall genes, including murE (Gardete et al., 2004)
and fmhB (Rohrer et al., 1999), which are also known to restore
MRSA susceptibility to b-lactams, also conferred genetic poten-
tiation to imipenem and other b -lactams by antisense interfer-
ence (data not shown).
To further examine drug sensitivity phenotypes associated
with partial inactivation of SAV1754, we tested the susceptibility
of the COL SAV1754-AS strain to a broad panel of knownvier Ltd All rights reserved
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Carbapenem Potentiators and Mode of Action Studiesantibiotics. As expected, SAV1754-AS displayed marked hyper-
sensitivity to DMPI, CDFI, and compound D (Figure 6). However,
SAV1754-AS chemical sensitivity phenotypes did not extend to
other mechanistic classes of antibiotics including inhibitors of
DNA gyrase (fluoroquinolones), DHFR (trimethoprim), RNA syn-
thesis (rifampicin), protein synthesis (polyketide, macrolide, or
oxazolidinones), or fatty acid synthesis (cerulein). In addition,
knockdown of SAV1754 expression did not result in hypersensi-
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Key:
strain DMPI CDFI Compound_D
RN4220::SAV1754 wt 7 2 0.4
RN4220::SAV1754 I18M 31 9 0.3
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Figure 5. Mutations Associated with DMPI
and CDFI Resistance in (MRSA) COL Are
Sufficient to Confer Resistance in (MSSA)
RN4220
Dose response for inhibition of representative
S. aureus strains transformed with I18M, P44Q,
or P257S mutations by DMPI (A), CDFI (B) and
Compound D (C). Allelic copies of SAV1754 were
introduced by homologous recombination yielding
a tandem duplication at the SAV1754 locus
(Figure S6). EC50 values for DMPI and CDFI with
the mutant strains (solid lines) are increased
approximately 5-fold compared with a control
strain containing a tandem wild-type SAV1754
duplication (dotted lines). In contrast, cross-resis-
tance of these alleles to compound D is not
observed. EC50 value determinations of allelic
pseudo-diploids to DMPI, CDFI, and compound
D are summarized. Cells were grown for 10 hr in
LB media supplemented with tetracycline (5 mg/
ml). Dose-response curves were fitted using a
four parameter logistic equation (GraphPad Prism
Software) with error bars representing the stan-
dard error of themean (SEM) of duplicate samples.
Figure 6. Genetic Depletion of SAV1754 by
Antisense Interference Restores COL
Susceptibility to b-Lactams
COL strains bearing either SAV1754-AS, the PBP2
positive control (PBP2-AS), or empty vector
(pEPSA5) were seeded in LB agar with 50 mM
xylose to induce antisense interference. Drugs
spotted are as follows: imipenem (12.8 mg; A1); er-
tapenem (51.2 mg; A2); cefepime (102.4 mg; A3);
ceftazidime (102.4 mg; A4); ceftriaxone (102.4 mg;
A5); piperacillin/tazobactam (25.6 mg; B1); vanco-
mycin (0.8 mg; B2); cerulein (12.8 mg; B3); rifam-
picin (0.003 mg; B4); azithromycin (0.4 mg; B5);
ciprofloxacin (0.1 mg; C1); levofloxacin (0.1 mg;
C2); trimethoprim (0.8 mg; C3); tetracycline (25.6 mg; C4); linezolid (1.6 mg; C5); compound D (0.0125 mg; D1); DMPI (0.8 mg; D2); CDFI (0.2 mg; D3); DMSO
(10 ml 20% stock; D4); 0.1M PBS (pH 6) and 10 mMMOPS (pH 7) (10 ml of each buffer spotted adjacent to one another; D5). Susceptibility was scored according
to zones of inhibition after 24 hr growth at 37C. SAV1754 hypersensitivity is restricted to two classes of antibiotics: (i) b-lactams which target PBPs, and (ii) the
proposed SAV1754 inhibitors (DMPI, CDFI, and compound D). Zone sizes for parallel spottings on inoculated media lacking xylose were identical to the vector
control (not shown).
tivity to other non b-lactam cell wall inhib-
itors tested, including fosfomycin, moe-
nomycin, teicoplanin, bacitracin, and
tunicamycin (data not shown). Thus
genetic depletion of SAV1754 in MRSA
provides chemical hypersensitivity phe-
notypes specific to target-selective inhib-
itors as well as b-lactams rather than
a pleiotropic antibiotic hypersensitization. Although genetic
inactivation of SAV1754 potentiates the activity of b-lactams,
no reciprocal relationship was observed; specifically, genetic
inactivation of PBP2 did not enhance the effect of DMPI, CDFI,
or compound D. Notwithstanding additional effects potentially
elicited by the SAV1754 antisense interference (for example
off-target SAV1753 effects), these results demonstrate that
genetic inactivation of SAV1754 in the MRSA COL strainChemistry & Biology 16, 837–848, August 28, 2009 ª2009 Elsevier Ltd All rights reserved 843
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produced by DMPI, CDFI, and compound D. Further, chemical
hypersensitivity phenotypes of SAV1754 reflect those achieved
by PBP2 and other cell wall mutants (manuscript in preparation),
implicating SAV1754 as performing a novel function that directly
or indirectly affects peptidoglycan synthesis or assembly.
DISCUSSION
Targeting SAV1754 Restores MRSA Susceptibility
to b-Lactams
By phenotypic screening for synthetic compounds that restore
MRSA susceptibility to carbapenems, we identified a new indole
class of compounds, DMPI and CDFI, which potentiate imipe-
nem activity across multiple methicillin-resistant Staphylococci.
DMPI and CDFI are predicted to elicit their carbapenem potenti-
ating effect by inhibiting SAV1754, a previously uncharacterized
gene product. AISS profiling of DMPI and CDFI, as well as the
previously reported inhibitor (compound D), for target-specific
chemical sensitivity across 245 essential genes tested revealed
SAV1754 as uniquely and prominently hypersensitive to each of
these agents, suggesting they share a common MOA. Further,
SAV1754 overexpression significantly reduced RN4220 suscep-
tibility to DMPI and CDFI, analogous to that previously reported
for compound D (Mott et al., 2008). Indeed, isolation of indepen-
dent DMPI resistant mutants in MRSA COL mapped to three
distinct mutations in SAV1754, each reducing COL susceptibility
to DMPI > 16-fold (MIC > 64 mg/ml) and each suppressing
DMPI’s potentiation of imipenem. Because these mutations
were not cross-resistant to multiple cell wall inhibitors tested, it
is unlikely they reflect a compensatory or bypass mechanism
of resistance. Interestingly, these mutations all map to the amino
terminal half of the SAV1754 protein, with the DMPI resistance
mutation P44Q mapping particularly close to the compound D
resistance mutation A48T previously reported (Mott et al.,
2008). These results, combined with allelic resistance studies,
demonstrate their sufficiency in MSSA strain RN4220 to confer
DMPI and CDFI resistance and strongly implicate SAV1754 as
their likely target. Consistent with this possibility, genetic deple-
tion of SAV1754 in MRSA dramatically increased COL sensitivity
to imipenem, congruent with the synergistic effects of both the
indole and anthranilic acid class inhibitors in combination with
imipenem. Thus, opposing phenotypes of b-lactam resistance
or restored susceptibility were achieved in MRSA by distinct
genetic alterations in SAV1754.
Transposon-mediated insertional mutants generated in MRSA
COL have identified an extensive list of genetic determinants,
which, if inactivated, restore susceptibility to b-lactams
(Berger-Ba¨chi and Rohrer, 2002; de Lencastre et al., 1999).
With few exceptions, such ‘‘auxillary’’ genes (e.g., femA, femB,
murE, and pbp2) are directly involved in cell wall biosynthesis.
The failure to identify SAV1754 by these means might reflect
its essential functional role and/or intrinsic transposon biases
precluding the likely occurrence of such insertion mutations.
The application of an antisense interference strategy, as used
here to demonstrate genetic inactivation of SAV1754 augments
imipenem activity against COL, suggests the broader utility of
this approach to identify additional genes sharing this pheno-
type. Indeed, preliminary results using targeted antisense inter-844 Chemistry & Biology 16, 837–848, August 28, 2009 ª2009 Elsevference in COL validates a number of cell wall genes whose inac-
tivation is known to restore MRSA susceptibility to b-lactams,
including murE (Gardete et al., 2004), fmhB (Rohrer et al.,
1999), murF (Sobral et al., 2003), and glmS (Komatsuzawa
et al., 2004) and identifies additional cell wall genes such as
murB, murC, and pbpA that share this phenotype (data not
shown).
Possible Role of SAV1754 as a Gram-Positive
Peptidoglycan Flippase
Although essentially all the genes comprising the peptidoglycan
biosynthetic pathway have been long since identified (Bugg and
Walsh 1992) and extensively characterized across Gram-posi-
tive and Gram-negative bacteria (van Heijenoort 2001, Green,
2002, El Zoeiby et al., 2003), one central participant—a flippase
required to translocate lipid II peptidoglycan precursors from the
cytoplasmic side of the cell membrane to the periplasmic surface
of the membrane—has remained largely elusive (Scheffers and
Pinho, 2005). However, two recent reports describe the E. coli
gene, murJ (mviN), as likely fulfilling this function (Ruiz, 2008;
Inoue et al., 2008).MurJ is predicted to encode a 14-membrane-
spanning inner membrane protein that is broadly conserved
among Gram-negative bacteria and essential for growth. More-
over,murJ conditional mutants possess reduced peptidoglycan
levels and a concomitant increase of cell wall precursors, result-
ing in an osmotic remedial lysis phenotype. Consistent with this
claim, MurJ is absent from the Mollicutes class of enodosymbi-
otic bacteria (includingMycoplasma spp.), which lack a peptido-
glycan cell wall. Therefore, an important question raised from
this work relates to the nature of the flippase activity in Gram-
positive bacteria.
We speculate that SAV1754, which is conserved among
Gram-positive bacteria (Figure S1A), might perform an analo-
gous peptidoglycan lipid II flippase function. Like murJ,
SAV1754 is essential for cell viability and is predicted to encode
a 14-transmembrane-spanning integral membrane protein,
which, if inactivated, results in similarly striking cell wall pheno-
types, including (i) decreased macromolecular synthesis of
peptidoglycan, (ii) accumulation of peptidoglycan precursors
(Mott et al., 2008), (iii) reduced peptidoglycan deposition by
Van-FL staining, and (iv) restored susceptibility of MRSA to a
broad diversity of b-lactams. In accordance with this suggestion,
SAV1754 is also a member of the same multidrug/oligosacchar-
idyl-lipid/polysaccharide protein superfamily asMurJ.Moreover,
SAV1754 shares three Pfam motifs characteristic of MurJ; an
250 N-terminal domain polysaccharide biosynthesis motif to
which DMPI, CDFI, and compound D resistance mutations
map, a MVIN motif spanning essentially the entire length of
SAV1754, and a C-terminal MatE motif (Figure S1B).
Like murJ, SAV1754 is also absent among Mycoplasma spp.,
which, as endosymbiont-living bacteria, lack a peptidoglycan
cell wall. Because 16S rRNA sequence roots Mycoplasma as
ancestrally related to Gram-positive bacteria but diverging
from the latter as recently as 65 million years ago, its parallel
genome reduction and cell wall loss further support the relation-
ship between SAV1754 function and cell wall biosynthesis. We
also note that by applying the bioinformatic deduction strategy
used to identify MurJ (N. Ruiz, 2008), a SAV1754 homolog
(2e-26) is identified in Eubacterium dolichum. Despite the reportier Ltd All rights reserved
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wheat germ agglutinin fluorescent staining (Maymo´-Gatell
et al., 1997), clear homologs of MurA through MurG, as well as
MraY and PBPs, were also identified. Thus, the assertion that
E. dolichum lacks a peptidoglycan cell wall must be revisited
(Maymo´-Gatell et al., 1997).
Limited similarity between SAV1754 and MurJ—despite our
assertion that they are functional orthologs—might reflect the
substantial evolutionary distance between E. coli and S. aureus
as well as their hydrophobic transmembrane domain structure
(Figure S5). Sequence divergence between these proposed
peptidoglycan flippases might also be attributed, in part, to
structural differences between lipid II peptidoglycan substrates
common to Gram-positive and Gram-negative bacteria. Not-
withstanding this possibility, B. subtilis encodes a protein
(BSU30050) sharing strong homology (1e-85) with SAV1754.
Yet B. subtilis and E. coli peptidoglycan share a common stem
peptide distinct from S. aureus. B. subtilis and Gram-negative
derived stem peptides contain meso-diamoinopimelic acid
(DAP) and no pentaglycine bridge, whereas S. aureus and
most other Gram-positive bacteria substitute DAP with L-lysine,
from which a pentaglycine bridge is conjugated (Scheffers and
Pinho, 2005). Therefore, biochemical assays are required to
measure the predicted flippase activity of SAV1754 and MurJ,
as well as confirm in vitro the effects of SAV1754 inhibitors,
and examine whether their possible inhibitory spectrum extends
to MurJ, as suggested by their modest activity against the per-
meabilized E. coli strain MB5746.
Chemical Genetic Synergism as an Approach
to Antibiotic Lead Discovery
An urgent need exists to develop new efficacious agents to treat
MRSA infections. Whereas significant efforts have focused on
single agents that fulfill this role (Silver, 2003, 2007; Payne
et al., 2007), the use of combination agents that augment spec-
trumgaps of existing therapeutics with proven safety profiles has
also gained general acceptance as a valid drug development
strategy (Walsh, 2000; Keith et al., 2005; Yeh et al., 2006; Hugon-
net et al., 2009). Indeed, whole-cell compound potentiation
screens offer significant advantages over biochemical or
target-based whole-cell screens. First, as in the case of an erta-
penem synergism screen, subinhibitory levels of ertapenem
broadly inhibit the penicillin-binding protein family, which is a
significant technical challenge by genetic means. Second,
provided the MOA of the queried antibiotic is specific and mech-
anistically conserved across bacteria, it serves as a chemical
surrogate to genetic strategies as a means to identify synergistic
agents targeting specific pathogens not amenable to mutagen-
esis. Finally, whereas the rationale of target-based screens is
to identify cognate inhibitors (which may or may not exist among
a finite screening library), synergism-based screens emphasize
the entire genome as possible targets of potentiation, thereby
increasing the likelihood that compounds of interest will be iden-
tified. However, critical to the success of this approach is the
need to rapidly determine the MOA of such growth inhibitory
compounds. This is typically achieved by classical drug-resis-
tant mutant analysis (Mott et al., 2008). AISS profiling as demon-
strated here and in the accompanying report (Donald et al.,
2009), provides a rapid chemical-genetic strategy linking growthChemistry & Biology 16, 8inhibitory compounds to their target according to gene-specific
compound hypersensitivity phenotype(s) identified among a
compendium of potential targets tested in parallel.
Although none of the compounds we report are sufficiently
potent in their current form—and significant chemical modifica-
tions would be required to advance their development—their
discovery and determined MOA strongly implicate SAV1754 as
a druggable target, which, if chemically inhibited, elicits the
desired potentiation of b-lactams. Because SAV1754 is broadly
conserved across Gram-positive bacteria and its phenotypes
implicate a central role in S. aureus cell wall biogenesis, it repre-
sents a new participant of this important pathway that a broad
diversity of antibiotics target. Thus, target-based screens are
warranted to identify new SAV1754 inhibitory classes with
improved antibiotic lead properties. More broadly, empiric
screening for synergistic agents to other existing antibiotics
that similarly restore susceptibility to MRSA or expand spectrum
to other bacterial pathogens, provides timely and pragmatic
alternatives to antibacterial drug discovery.
SIGNIFICANCE
Staphylococcus aureus is a major nosocomial and commu-
nity-acquired pathogen that has acquired an alarming resis-
tance to practically all antibiotics. Here we identify antibac-
terial inhibitors (DMPI and CDFI) that restore susceptibility
of methicillin-resistant S. aureus (MRSA) to carbapenem
class b-lactam antibiotics. Genetic studies confirm that
these agents as well as the structurally distinct inhibitor,
compound D (Mott et al., 2008), target the functionally unan-
notated protein, SAV1754. First, we demonstrate SAV1754 is
specifically hypersensitive to each of these agents among
an extensive collection of essential genes examined by
AISS profiling, as described in the accompanying paper
(Donald et al., 2009) in this issue of Chemistry & Biology.
Conversely, SAV1754 overexpression confers resistance to
these compounds. Further, DMPI-resistant mutations in
MRSA map to SAV1754 and are sufficient to confer resis-
tance to DMPI and CDFI as well as suppress the synergistic
effects of these agents in combination with imipenem.
Importantly, SAV1754 antisense-induced inactivation in
MRSA phenocopies the potentiating effect of these
compounds in restoring b-lactam activity, thereby providing
a mechanistic basis for their synergistic effects. SAV1754
inhibitors also disrupt peptidoglycan synthesis as judged
by whole cell macromolecular labeling and fluorescence
staining of nascent peptidoglycan. Interestingly, SAV1754
is essential for S. aureus growth and is structurally related
to the recently reportedMviN/MurJ peptidoglycan precursor
flippase in Escherichia coli (Ruiz, 2008). However, whereas
MurJ homologs are restricted to Gram-negative bacteria,
SAV1754 family members are conserved across Gram-posi-
tive bacteria. Based on these data, we propose SAV1754
provides a peptidoglycan flippase function in cell wall
biosynthesis among Gram-positive bacteria and that inhibi-
tors of this target might possess therapeutic potential alone
or as combination agents with b-lactams. More broadly, our
work highlights an antibacterial discovery strategy for new
agents that synergize with existing antibiotics, thereby37–848, August 28, 2009 ª2009 Elsevier Ltd All rights reserved 845
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EXPERIMENTAL PROCEDURES
S. aureus Strains
MSSA strain EP167 is the RN450 lab strain transformed with antisense vector
pEPSA5 (Forsyth et al., 2002) and was used in macromolecular labeling exper-
iments and for compound susceptibility testing. MSSA strain RN4220 was
used as host for antisense or overexpression plasmids, or for chromosomal
gene targeting vectors. RN4220 is a lab strain, selected originally from
a phage-cured wild-type isolate of NCTC 832 (RN450) for enhanced transfor-
mation competency (Novick, 1991). Methicillin-resistant S. aureus MB 5393
(COL) and S. epidermidisMB 6255 (CLB 26329) were used in synergy studies.
Synergy Studies
Standard protocols were used to determine the MIC values of compounds
(Amsterdam, 2005 and available from the Clinical and Laboratories Standards
Institute as protocol M07-A7; www.clsi.org). MIC values are defined as the
lowest concentration of agents either singly or in combination that completely
inhibited visible growth. The ‘‘checkerboard’’ techniquewas used to determine
whether combinations of two antibacterial compounds demonstrate synergy
(Amsterdam, 2005). The analysis was performed using 96-well polystyrene
microtiter plates. All strains were diluted to a final concentration of 5 3 105
CFU/ml in fresh cation-adjusted Mueller Hinton broth with or without 2%
NaCl. Data were interpreted by calculating the fractional inhibitory concentra-
tion (FIC) values and indexes (FICI). The FIC was determined for each
compound by dividing the MIC of each compound when used in combination,
by the MIC of that compound when used alone. The FICI is the sum of the
two FIC values for each compound in an active combination. That is, FICA =
MICA-comb / MICA-alone; FICI = FICA + FICB. An FICI value% 0.5 was interpreted
as synergistic.
Plasmid and Strain Construction
Polymerase chain reaction (PCR) primers (IDT) used in plasmid and strain
construction are listed in Table S5. Plasmid pTET15 (GenBank accession
FJ859896) was used for episomal expression of SAV1754. This shuttle vector
contains a tetracycline-inducible promoter, the regulatory tetR repressor gene
and chloramphenicol (for S. aureus) and ampicillin (for E. coli) selectable
markers. GenomicS. aureusDNAwas preparedwith aWizzard kit (Promega)
and SAV1754 fragments were PCR amplified with Platinum pfx polymerase
(Invitrogen). The SAV1754 COL strain ORF was subcloned using vector and
PCR primer BamHI and SmaI sites. The resulting expression plasmid was
verified by DNA sequencing prior to introduction into the RN4220 strain by
electroporation (Kraemer and Iandolo 1990). Transformants were selected
on LB agar supplemented with 34 mg/ml chloramphenicol. Integrating plasmid
pSA3182-UC was used to introduce additional copies of the SAVl754 gene at
the endogenous chromosomal locus (RN4220 strain) via homologous recom-
bination. This vector was derived from pSA3182 (Xia et al., 1999) by
substituting a 1.1 kb EcoRI DNA fragment (from phage phi-11) for a 0.8 kb frag-
ment containing the pUC plasmid replication origin (to permit propagation in
E. coli) and by adding a Sall site to facilitate subcloning. Genomic 2.l kb frag-
ments spanning the SAVl754 gene and flanking sequence were PCR amplified
from the COL parental strain and DMPI-resistant mutants and subcloned into
vector BamHI and Sall sites. After DNA sequence confirmation, the resulting
plasmids were electroporated into RN4220 and stable transformants selected
on LB agar supplemented with 5 mg/ml tetracycline. Primary colonies were
purified by two rounds of streaking on this selective media. The structure of
the SAV1754 locus in transformants harboring cointegrated vector was
confirmed by genomic PCR using a combination of vector-specific primers
and primers external to the introduced DNA fragment (primer pairs P3/P4,
P3/P5, P4/P6, and P5/P6; Table S5 and Figure S6). The majority of transform-
ants contained only two genomic copies of targeting vector. The presence of
additional copies (in10%) was detected by PCRwith vector-specific primers
P5/P6. The tandem copies of SAV1754 were PCR amplified (primers P3/P5
and P4/P6) and DNA sequenced to confirm the presence of wild-type and
targeted P44Q, I18M, and P257S alleles.846 Chemistry & Biology 16, 837–848, August 28, 2009 ª2009 ElsevMacromolecular Labeling
Selective inhibition of peptidoglycan synthesis was measured in living cells of
S. aureus using the macromolecule radiolabeling assay described by Onishi
et al. with adaptations for Staphylococcus (Onishi, 1996). MSSA strain
EP167 was grown in nutrient broth (Difco) with 1% NaCl and chloramphenicol
(34 mg/ml) to select for antisense plasmid pEPSA5 (Forsyth et al., 2002).
Aliquots were transferred to wells of microtitration plates containing com-
pound dilutions and radioactive precursors of macromolecules. Radiolabeled
substrates were: peptidoglycan, [14C-(U)]-glycine (0.5 mCi/ml); DNA, [2-14C]-
thymidine (0.25 mCi/ml); phospholipid, [2-3H]-glycerol (0.25 mCi/ml), RNA,
[5, 6-3H]-uridine (0.075 mCi/ml), and protein L-[4, 5-3H]-leucine (2.5 mCi/ml).
Erythromycin (10 mg/ml) was included in all assays except protein synthesis
to counteract the effects of the stringent control. After 30 min incubation at
37C, TCA 5% (final) was added to stop incorporation. Precipitates were
collected on glassmicrofiber filtermats using a cell harvester (Micro 96,Molec-
ular Devices).
AISS Profiling Assay
AISS profiles were generated for compounds as described in the accompa-
nying paper by Phillips and colleagues published in this issue of Chemistry &
Biology (Donald et al., 2009). Briefly, 245 strains each containing a different
inducible antisense interference plasmid targeting an essential gene in
S. aureus RN4220 (MSSA) were pooled into 24 different bins of 6–12 strains
each. The bins were then grown each at a different concentration of xylose
inducer (ranging from 1.8 to 55 mM) for 20 population doublings either in
the presence of compound being tested or as a 2% DMSO mock treatment
control. Strain bin growth was performed in 384-well plates (Costar 3680)
on a fully automated system using LB media containing chloramphenicol
(34 mg/ml) over three cycles of growth ranging from 5 to 7 hr each for a total
time of 18 hr in a total volume of 50 ml. At the end of the growth period cells
from all 24 bins were pooled for each compound treatment or DMSO mock
control. Pooled cells were then lysed and subjected to multiplex PCR to
amplify specific antisense markers for each strain. Strain specific markers
were subsequently identified and peak areas quantitated by DNA fragment
analysis on an ABI 3730 genetic analyzer. Peak areas were then normalized
and strain depletion ratios were calculated. Statistical significance was deter-
mined as a p value utilizing an error model generated for each individual strain
across a discrete set of known standards and unknown test samples selected
to represent total coverage of all strains within the array set (see also Donald
et al., 2009). Log depletion ratios and p values for all strains for each of the
compound treatments shown in Figure 3A can be found in Tables S6 and
S7. The antisense strains described in this work are available for noncommer-
cial use following the standard Merck Material Transfer Agreement (MTA) and
clearance procedures.
Fluorescence Staining
An equimolar ratio of vancomycin antibiotic (Sigma) and a BODIPY FL conju-
gate of vancomycin (Van-FL, Invitrogen), at a sub-inhibitory concentration of
0.5 mg ml1, was used to label newly synthesized peptidoglycan precursors
as previously described (Pinho and Errington, 2003). In short, a culture of
S. aureus RN4220 (MSSA) was grown for 16 hr in tryptic soy broth (TSB) at
37C in the presence of 0.125 M D-Serine amino acid (Sigma), to allow for
incorporation of D-serine amino acid in place of D-alanine amino acid into
the propagating cell wall. The culture was diluted 1/50 into fresh TSB supple-
mented with 0.125 M D-Serine and continued to grow at 30C until mid-log
phase (OD600 = 0.5). The culture was then divided into four 1ml aliquots
and appropriate antibiotics were added at 2X their respective MIC: DMPI
2 mg ml-1, Compound D 0.04 mg ml1, Novobiocin 0.3 mg ml1, and no drug
treatment control. The cultures were further incubated at 30C for 50 min.
The cultures were then washed once and resuspended in the same volume
of fresh TSB in the absence of D-serine but with appropriate antibiotics (as
stated above) and incubated at 30C for 15 min, to allow for incorporation of
D-alanine amino acid. The cells were spun and Van/Van-FLmixture was added
to each culture and incubated at room temperature for 10 min. The samples
were applied to poly-lysine coated chambered slides and washed once with
PBS and resuspendedwith VECTASHIELD (Vector Laboratories). The samples
were immediately observed by fluorescence microscopy.ier Ltd All rights reserved
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COL strains transformed with antisense interference plasmids or vector
control were grown overnight in Luria Bertani (LB) Miller broth at 37C contain-
ing 34 mg/ml chloramphenicol. Assay plates were prepared by seeding 107
cells/ml of each culture into 48C cooled LB Miller agar containing 34 mg/ml
chloramphenicol, and 0, 25, 50, 100, or 200 mM xylose. Agar plates were
allowed to set and then spotted with 10 ml of each drug and incubated at
37C with humidity for 18 hr.
SUPPLEMENTAL DATA
Supplemental Data include six figures and seven tables and can be found with
this article online at http://www.cell.com/chemistry-biology/supplemental/
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